PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed
    7/22/2024

    New to PP405? There is a guide in the encyclopedia. Read the guide →
    At a glance
    In this research recruitment post, the primary subjects mentioned are
    💧 PP405 (topical) once-a-week 16 weeks
    the tone is 😐 neutral.

    Other terms

    PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community Article of all potential future cures

       25 upvotes 1 year ago
      Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

      community Hair transplants and PP405 - Irregular density concern

       18 upvotes 5 months ago
      The conversation discusses concerns about getting a hair transplant with the potential release of a new treatment, PP405, which may regrow dormant hair follicles. The user is currently using Minoxidil, Derma, and Keto but is waiting to start finasteride or dutasteride.

      community What new hair-loss treatments actually look exciting right now (Oct 2025)

       171 upvotes 11 months ago
      New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

      community Regrew my hair - 12 month update.

       3963 upvotes 1 year ago
      A user successfully regrew hair over 12 months using topical minoxidil, topical finasteride, microneedling, and supplements, with no side effects. They credit their success to consistency and a comprehensive routine.

    Related Research

    6 / 6 results
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      PP405 in Alopecia: An Emerging Molecule Worth Investigating

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
      Review of the 2024 American Academy of Dermatology Annual Meeting

      research Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting

      April 2024
      This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

      research Emerging pharmacotherapies for Androgenetic Alopecia

      June 2026 in “Expert Opinion on Pharmacotherapy”
      This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.